慢性骨髓性白血病治疗市场按药物类型、给药途径、分销管道和地区划分

2025 年全球慢性骨髓性白血病治疗市场规模估计为 90.4 亿美元，预计到 2032 年将达到 142.4 亿美元，2025 年至 2032 年的复合年增长率为 6.7%。

数字。 2025年慢性骨髓性白血病治疗市场占有率（按地区）

慢性骨髓性白血病(CML) 是一种始于骨髓并导致白血球过度生成的癌症。 CML 主要是由于基因异常导致骨髓中髓系细胞不受控制地增殖并在血液中积聚而引起的。如果不及时治疗，CML 会从慢性期发展到加速期，最终发展为急变期。近年来，全球慢性骨髓性白血病治疗市场经历了显着成长，这得益于蛋白酪氨酸激酶抑制剂等创新标靶治疗药物的推出，这些药物改善了 CML 患者的临床结果和生活品质。

市场动态：

全球慢性骨髓性白血病治疗市场受到全球范围内慢性骨髓性白血病盛行率不断上升以及人们对早期诊断和治疗认识不断提高的推动。此外，比传统化疗更有效、更安全的新型标靶治疗药物的开发和核准正在推动市场成长。然而，标靶治疗的高价格仍然是一个重大挑战，尤其是在对价格敏感的新兴市场。从积极的一面来看，不断增长的医疗支出和对优质药品的需求为市场参与者提供了有利可图的机会。此外，在预测期内，评估新治疗方法的临床试验的合作研究可能会进一步扩大市场范围。

本研究的主要特点

本报告对全球慢性骨髓性白血病治疗市场进行了详细分析，并以 2024 年为基准年，展示了预测期（2025-2032 年）的市场规模和复合年增长率。

它还强调了各个领域的潜在商机，并说明了该市场的有吸引力的投资提案矩阵。

它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的主要考察。

全球慢性骨髓性白血病治疗市场的主要企业根据公司亮点、产品系列、关键亮点、绩效和策略等参数进行分析。

研究中介绍的主要企业包括 Teva Pharmaceutical Industries Ltd.、F. Hoffmann-La Roche Ltd.、诺华公司、赛诺菲、百时美施贵宝公司、辉瑞公司、工业有限公司、信达生物製药公司、Viatris Inc.、Lupin、Million Health Pharmaceuticals、Celon Labs 和 Fresenius Labs AGbs。

本报告的见解将使负责人和企业经营团队能够就未来的产品发布、高端市场策略、市场扩张和行销策略做出明智的决策。

全球慢性骨髓性白血病治疗市场报告涉及该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。

相关人员可以透过用于分析全球慢性骨髓性白血病治疗市场的各种策略矩阵来促进决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要

第三章市场动态、法规与趋势分析

• 市场动态
• 影响分析
• 主要亮点
• 监管情景
• 产品发布/核准
• PEST分析
• 波特分析
• 併购场景
• 流行病学

第四章。慢性骨髓性白血病治疗市场（按药物类型），2020-2032 年（十亿美元）

• 蛋白酪氨酸激酶抑制剂
• Imatinib（Glivac）
• Dasatinib（Sprycel）
• 尼洛替尼（Tasigna）
• Bosutinib（Bosurif）
• Ponatinib（Iclusig）
• 阿西米尼（Sembrix）
• 其他的
• 抗代谢物
• 其他的

第五章。慢性骨髓性白血病治疗市场，依给药途径，2020-2032 年（十亿美元）

• 口服
• 肠外
• 外用
• 其他（鼻腔等）

第六章。慢性骨髓性白血病治疗市场，按分销管道，2020-2032 年（十亿美元）

• 医院药房
• 零售药局
• 网路药局

第七章全球慢性骨髓性白血病治疗市场，按地区，2020-2032 年，价值（十亿美元）

• 北美洲
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东
• 非洲

第八章竞争格局

• Teva Pharmaceutical Industries Ltd
• Hoffmann-La Roche Ltd.
• Novartis AG
• Sanofi
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Innovent Biologics, Inc.
• Viatris Inc.
• Lupin
• Million Health Pharmaceuticals
• Celon Labs
• Fresenius Kabi AG

第九章分析师建议

• 机会
• 分析师观点
• Coherent Opportunity Map

第十章参考文献与调查方法

• 参考
• 调查方法
• 关于出版商

Global Chronic Myeloid Leukemia Treatment Market is estimated to be valued at USD 9.04 Bn in 2025 and is expected to reach USD 14.24 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.7% from 2025 to 2032.

Figure. Chronic Myeloid Leukemia Treatment Market Share (%), By Region 2025

Chronic myeloid leukemia (CML) is a type of cancer that starts in the bone marrow and leads to an overproduction of white blood cells. The main driver of CML is a genetic abnormality that leads to unrestrained growth of myeloid cells in the bone marrow and their accumulation in the blood. If left untreated, CML progresses from a chronic phase to an accelerated phase and finally to a blast crisis. The global chronic myeloid leukemia treatment market has witnessed significant growth in recent times owing to the introduction of innovative targeted therapies such as tyrosine kinase inhibitors that have improved the clinical outcome and quality of life of CML patients.

Market Dynamics:

The global chronic myeloid leukemia treatment market is driven by the increasing prevalence of CML worldwide and growing awareness about early diagnosis and treatment. Moreover, the development and approval of novel targeted drugs with better efficacy and safety profiles compared to conventional chemotherapy have boosted the market growth. However, the high cost of targeted therapies remains a key challenge, especially in price-sensitive developing markets. On the positive side, increasing healthcare expenditure and demand for premium drugs provide lucrative opportunities for market players. Additionally, collaborations for clinical trials evaluating novel treatment approaches will further expand the market reach during the forecast period.

Key features of the study:

This report provides in-depth analysis of the global chronic myeloid leukemia treatment market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global chronic myeloid leukemia treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi, Bristol-Myers Squibb Company, Pfizer Inc., Takeda Pharmaceutical Company Limited, Innovent Biologics, Inc., Viatris Inc., Lupin, Million Health Pharmaceuticals, Celon Labs, and Fresenius Kabi AG

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global chronic myeloid leukemia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic myeloid leukemia treatment market

Detailed Segmentation-

• Drug Type Insights
  • Tyrosine Kinase Inhibitors
  • Imatinib (Gleevac)
  • Dasatinib (Sprycel)
  • Nilotinib (Tasigna)
  • Bosutinib (Bosulif)
  • Ponatinib (Iclusig)
  • Asciminib (Scemblix)
  • Others
  • Antimetabolites
  • Others
• Route of Administration Insights
  • Oral
  • Parenteral
  • Topical
  • Others (Nasal, etc.)
• Distribution Channel Insights
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Company Profiles:
  • Teva Pharmaceutical Industries Ltd
  • Hoffmann-La Roche Ltd.
  • Novartis AG
  • Sanofi
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Innovent Biologics, Inc.
  • Viatris Inc.
  • Lupin
  • Million Health Pharmaceuticals
  • Celon Labs
  • Fresenius Kabi AG

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Chronic Myeloid Leukemia Treatment Market, By Drug Type
  • Chronic Myeloid Leukemia Treatment Market, By Route of Administration
  • Chronic Myeloid Leukemia Treatment Market, By Distribution Channel
  • Chronic Myeloid Leukemia Treatment Market, By Region

3. Market Dynamics, Regulations, And Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Epidemiology

4. Chronic Myeloid Leukemia Treatment Market, By Drug Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Tyrosine Kinase Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Imatinib (Gleevac)
• Dasatinib (Sprycel)
• Nilotinib (Tasigna)
• Bosutinib (Bosulif)
• Ponatinib (Iclusig)
• Asciminib (Scemblix)
• Others
• Antimetabolites
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Chronic Myeloid Leukemia Treatment Market, By Route of Administration, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Parenteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Topical
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others (Nasal, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Chronic Myeloid Leukemia Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Chronic Myeloid Leukemia Treatment Market, By Region, 2020-2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Drug Type , 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel , 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

8. Competitive Landscape

• Teva Pharmaceutical Industries Ltd
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Hoffmann-La Roche Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Takeda Pharmaceutical Company Limited
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Innovent Biologics, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Viatris Inc.
• Lupin
• Million Health Pharmaceuticals
• Celon Labs
• Fresenius Kabi AG

9. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. References and Research Methodology

• References
• Research Methodology
• About us